Unit for Thrombosis Research, Institute of Public Health, The University of Southern Denmark, c/o Department of Clinical Biochemistry, Hospital of South West Denmark, Finsensgade 35, DK-6700 Esbjerg, Denmark.
Eur J Clin Pharmacol. 2011 Nov;67(11):1169-74. doi: 10.1007/s00228-011-1045-0. Epub 2011 May 12.
Vitamin K antagonist (VKA) treatment can successfully prevent thromboembolic complications, but the modality has a narrow therapeutic window and numerous interactions with other pharmaceuticals. The aim of the study reported here was to describe the use of co-medications and the prevalence of polypharmacy among patients treated with VKA.
In a cross-sectional study, 250 consecutive patients (65% male, median age 68 years, most common indication for VKA treatment: atrial fibrillation) in the maintenance phase of VKA treatment were interviewed about their use of prescription medications, over-the-counter drugs and alternative medicines during the last 7 days.
The interviewed patients used a median of five medications (range 1-13), including VKA. Approximately 50% of the patients also took alternative medicines. A wide range of conventional and alternative medicines were used, several of which harbour possible interactions with VKA. Polypharmacy was defined as the use of five or more medications, excluding alternative medicines. The group of polypharmacy patients included 53% of the study population. The use of amiodarone, age >50 years, the indication for VKA treatment being atrial fibrillation or mechanical heart valves and diabetes were independent predictors of polypharmacy.
The results of this study highlight that polypharmacy is a common phenomenon among patients on anticoagulant medication, particularly among elderly patients or those suffering from cardiovascular disease or diabetes.
维生素 K 拮抗剂 (VKA) 治疗可成功预防血栓栓塞并发症,但该方法治疗窗较窄,且与许多其他药物存在相互作用。本研究旨在描述 VKA 治疗患者合并用药情况和多药治疗的流行情况。
在一项横断面研究中,对 250 例连续 VKA 维持治疗患者(65%为男性,中位年龄 68 岁,最常见的 VKA 治疗指征:心房颤动)进行了访谈,了解他们在过去 7 天内使用处方药、非处方药和替代药物的情况。
接受访谈的患者使用了中位数为 5 种药物(范围 1-13 种),包括 VKA。约 50%的患者还服用了替代药物。使用了范围广泛的常规和替代药物,其中一些药物可能与 VKA 存在相互作用。多药治疗定义为使用 5 种或更多种药物(不包括替代药物)。多药治疗组患者占研究人群的 53%。胺碘酮的使用、年龄>50 岁、VKA 治疗的指征为心房颤动或机械性心脏瓣膜病以及糖尿病是多药治疗的独立预测因素。
本研究结果表明,多药治疗是抗凝药物患者中常见的现象,尤其是老年患者或患有心血管疾病或糖尿病的患者。